Vivacelle Bio, Inc. Announces FDA Clearance to Enroll Patients into a Phase IIa Clinical Trial of VBI-S for Elevation of Blood Pressure in Subjects Who Have Shock Due to Sepsis

62

CHICAGO–(BUSINESS WIRE)–Vivacelle Bio received FDA clearance to proceed with its trial of VBI-S, a groundbreaking therapy for shock due to sepsis….

 

 

 

http://www.businesswire.com/news/home/20190708005192/en/Vivacelle-Bio-Announces-FDA-Clearance-Enroll-Patients